Progesterone and Allopregnanolone in ME/CFS
This section covers the evidence base for oral micronized progesterone as a potential therapeutic agent in ME/CFS, motivated by the Schacterle & Komaroff (2004) finding that approximately 30% of ME/CFS patients improve during pregnancy. The proposed mechanisms are: (1) Th2 immunoshift and Treg elevation via progesterone-induced blocking factor (PIBF); (2) allopregnanolone production (GABA-A potentiation, HPA calming, sleep improvement); (3) progesterone receptor-mediated anti-inflammatory signaling. Two null results from CFS hormone studies confirm that ME/CFS is not characterized by progesterone deficiency, supporting a pharmacological rather than replacement rationale.
1 Meltzer-Brody et al. 2018 — Brexanolone for Postpartum Depression (Phase 3 RCTs)
Full Citation:: Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. “Brexanolone injection in post-partum depression: two multicentre, double-blind, randomized, placebo-controlled, phase 3 trials.” Lancet. 2018;392(10152):1058–1070. DOI:: 10.1016/S0140-6736(18)31551-4 PMID:: 30177236 Study Design:: Two phase 3 double-blind RCTs at 30 US sites; Study 1 n=138 (BRX60, BRX90, placebo); Study 2 n=108 (BRX90, placebo). 60-hour IV infusion. Key Findings::
- Study 1: BRX 60 mcg/kg/h reduced HAM-D by 19.5 points vs 14.0 placebo (p=0.0013); BRX 90 mcg/kg/h reduced by 17.7 points (p=0.0252)
- Study 2: BRX 90 mcg/kg/h reduced HAM-D by 14.6 points vs 12.1 placebo (p=0.0160)
- Rapid onset (significant effect within 60 hours); effects sustained through 30-day follow-up
- Brexanolone is synthetic IV allopregnanolone; acts as GABA-A receptor positive allosteric modulator
- Common adverse events: sedation, dizziness, somnolence, headache; 4% syncope/presyncopeConclusion:: Establishes proof-of-concept for the allopregnanolone route: exogenous GABA-A potentiation via allopregnanolone produces rapid, clinically meaningful effects on a neuroendocrine–immune disorder. Directly supports the hypothesis that oral micronized progesterone (generating endogenous allopregnanolone) could produce analogous effects in ME/CFS, particularly HPA calming and sleep improvement. Limitations:: IV delivery only (not oral); PPD is not ME/CFS; follow-up limited to 30 days; REMS program required; modest effect sizes; presyncope adverse event requires monitoring. Certainty:: 0.82
2 Meltzer-Brody & Kanes 2020 — Allopregnanolone in PPD: Pathophysiology and Treatment
(Meltzer-Brody and Kanes 2020)
Full Citation:: Meltzer-Brody S, Kanes SJ. “Allopregnanolone in postpartum depression: Role in pathophysiology and treatment.” Neurobiology of Stress. 2020;12:100212. DOI:: 10.1016/j.ynstr.2020.100212 PMID:: 32435663 Study Design:: Narrative review; no original data. Key Findings::
- Allopregnanolone is a GABA-A receptor positive allosteric modulator; pregnancy levels are 10--100-fold above non-pregnant baseline
- Postpartum allopregnanolone withdrawal is proposed to precipitate PPD in sensitive individuals
- Brexanolone inhibits inflammatory signaling post-infusion, suggesting an anti-inflammatory effect secondary to GABA modulation
- Future oral neurosteroids (zuranolone, ganaxolone) may replicate IV brexanolone via oral route
- HPA axis dysregulation (elevated CRH, altered cortisol feedback) is partially normalized by allopregnanoloneConclusion:: Provides mechanistic framework connecting allopregnanolone deficiency, GABA-A dysfunction, HPA dysregulation, and inflammation — all of which overlap with ME/CFS pathophysiology. Supports the hypothesis that oral progesterone-derived allopregnanolone could address multiple ME/CFS disease mechanisms simultaneously. Limitations:: Narrative review; PPD-focused; ME/CFS is a different condition with different etiology; direct evidence in ME/CFS absent. Certainty:: 0.52
3 Szekeres-Bartho & Schindler 2019 — Progestogens and Immunology
(Szekeres-Bartho and Schindler 2019)
Full Citation:: Szekeres-Bartho J, Schindler AE. “Progestogens and immunology.” Best Practice & Research Clinical Obstetrics & Gynaecology. 2019;60:16–24. DOI:: 10.1016/j.bpobgyn.2019.07.001 PMID:: 31345741 Study Design:: Authoritative review by leading PIBF researcher; summarises decades of mechanistic work. Key Findings::
- Progesterone binds lymphocyte receptors to induce production of progesterone-induced blocking factor (PIBF)
- PIBF increases Th2 cytokine production (IL-4, IL-6, IL-10) and inhibits NK cell degranulation
- This Th2 shift and NK suppression underlies the immune tolerance of pregnancy
- Natural progesterone and some synthetic progestins (dydrogesterone) induce PIBF; others (medroxyprogesterone acetate) do not
- PIBF-mediated NK suppression reduces immune surveillance --- potentially beneficial for ME/CFS (where NK overactivation may contribute to symptoms) but must be weighed against infection riskConclusion:: Provides the central immunological mechanism for the oral progesterone hypothesis in ME/CFS. The Th2 shift and NK suppression mediated by PIBF directly correspond to the immunological changes associated with pregnancy-related ME/CFS improvement. Limitations:: Review article; most mechanistic data from pregnancy immunology, not immune dysfunction conditions; NK suppression effect may be context-dependent. Certainty:: 0.58
4 Raghupathy et al. 2009 — PIBF-Mediated Cytokine Shift
Full Citation:: Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. “Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery.” Journal of Reproductive Immunology. 2009;80(1–2):91–99. DOI:: 10.1016/j.jri.2009.01.004 PMID:: 19371956 Study Design:: In vitro lymphocyte stimulation study; n=72 women (30 recurrent miscarriage, 18 preterm delivery, 11 normal pregnancy, 13 non-pregnant controls); cytokine measurement with and without PIBF exposure. Key Findings::
- PIBF significantly increased IL-4, IL-6, and IL-10 (Th2 cytokines) in pregnancy-associated groups
- Th1:Th2 cytokine ratios were reduced in PIBF-treated samples
- No significant Th2-shifting effect observed in non-pregnant controls
- The Th1-to-Th2 cytokine shift is dose-dependent and reproduces the immunological profile of successful pregnancyConclusion:: Provides direct experimental evidence for the PIBF–Th2 cytokine shift mechanism. The absence of effect in non-pregnant controls raises the important question of whether ME/CFS patients (who are not pregnant) would respond similarly, or whether progesterone-receptor expression on immune cells differs. Limitations:: In vitro only; non-pregnant controls unresponsive; unknown whether ME/CFS patients have the progesterone-receptor-bearing lymphocytes required for PIBF production; small group sizes. Certainty:: 0.55
5 Hierweger et al. 2019 — Progesterone Modulates T Cells via Glucocorticoid Receptor
Full Citation:: Hierweger AM, Engler JB, Friese MA, et al. “Progesterone modulates the T-cell response via glucocorticoid receptor-dependent pathways.” American Journal of Reproductive Immunology. 2019;81(4):e13084. DOI:: 10.1111/aji.13084 PMID:: 30604567 Study Design:: In vitro murine study; splenic T cells from pregnant and non-pregnant mice incubated with progesterone or dexamethasone. Key Findings::
- Progesterone and dexamethasone selectively induced T-cell death while sparing regulatory T cells (Tregs)
- Mechanism is glucocorticoid receptor (GR) dependent, not progesterone receptor (PR) dependent
- Result: preferential enrichment of Treg proportion in progesterone-exposed immune cultures
- Progesterone cross-reacts with GR at pharmacological concentrations, explaining immunosuppressive effectsConclusion:: Identifies a second mechanism (beyond PIBF) by which progesterone elevates Tregs: GR cross-activation inducing selective effector T-cell apoptosis. This is pharmacologically important because it implies that pharmacological (supratherapeutic) progesterone doses — as in oral supplementation — may produce stronger immunosuppressive effects via GR than physiological progesterone via PR. Limitations:: Murine in vitro only; GR cross-activation requires concentrations above physiological range; in vivo bioavailability differences from in vitro conditions; direct human validation absent. Certainty:: 0.38
6 Andreen et al. 2006 — PK of Oral Progesterone: Allopregnanolone Production
Full Citation:: Andreen L, Spigset O, Andersson A, Nyberg S, Backström T. “Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone.” Maturitas. 2006;54(3):238–244. DOI:: 10.1016/j.maturitas.2005.11.005 PMID:: 16406399 Study Design:: Open-label pharmacokinetic study; n=8 postmenopausal women; single and repeated oral dosing of 20 mg progesterone. Key Findings::
- Oral 20 mg progesterone twice daily produced plasma allopregnanolone concentrations matching physiological mid-luteal phase levels
- Confirms that oral micronized progesterone functions as a prodrug for allopregnanolone
- First-pass hepatic conversion (5alpha-reductase, 3alpha-HSD) produces substantial allopregnanolone with oral route
- Allopregnanolone peak: approximately 5--15 ng/mL at 1--2 hours post doseConclusion:: Critical pharmacokinetic evidence establishing that oral micronized progesterone at clinical doses (100–200 mg = 5–10x the study dose) will generate clinically significant allopregnanolone. This bridges the brexanolone (IV allopregnanolone) proof-of-concept to the oral micronized progesterone hypothesis for ME/CFS. Limitation: only 20 mg studied; 100–200 mg doses in clinical use will produce higher concentrations with potentially greater sedation and GABA effects. Limitations:: Very small n=8; postmenopausal only; only 20 mg dose studied; no sleep or immune endpoints; extrapolation to clinical 100–200 mg doses requires caution. Certainty:: 0.42
7 Zhao et al. 2012 — Continuous vs Cyclic Progesterone: Receptor Downregulation
Full Citation:: Zhao L, Morgan TE, Mao Z, et al. “Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles.” PLoS One. 2012;7(2):e31267. DOI:: 10.1371/journal.pone.0031267 PMID:: 22393359 Study Design:: Animal study (ovariectomized rats); qRT-PCR analysis of hippocampal gene expression under four conditions: estradiol + cyclic progesterone, estradiol + continuous progesterone, estradiol only, OVX control. Key Findings::
- Cyclic progesterone with estradiol restored neuroprotective gene profiles (bioenergetics, anti-inflammatory, synaptic plasticity)
- Continuous progesterone with estradiol produced gene expression patterns indistinguishable from hormone-depleted OVX conditions
- Continuous exposure appears to downregulate progesterone receptors and downstream neuroprotective pathways
- Inflammatory marker expression was higher under continuous vs cyclic progesteroneConclusion:: Key safety and efficacy concern for the oral progesterone ME/CFS hypothesis. Continuous daily progesterone supplementation may attenuate or abolish therapeutic effects through receptor downregulation. Implies that cyclic dosing regimens (e.g., days 1–14 of a 28-day cycle, or intermittent pulsing) would be pharmacologically preferable to continuous daily dosing. Limitations:: Rodent model only; translational relevance uncertain; does not study immune endpoints; hippocampal-focused; clinical protocols for ME/CFS not tested. Certainty:: 0.38
8 Andreen et al. 2009 — Biphasic GABA-A Effects of Allopregnanolone
Full Citation:: Andreen L, Nyberg S, Turkmen S, van Wingen G, Fernandez G, Backström T. “Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABA-A modulators.” Psychoneuroendocrinology. 2009;34(8):1121–1132. DOI:: 10.1016/j.psyneuen.2009.02.003 PMID:: 19272715 Study Design:: Review and analysis of human experimental data; not a primary RCT. Key Findings::
- Allopregnanolone produces biphasic dose-response at GABA-A receptors: low concentrations (luteal-phase equivalent, approximately 1--5 nM) paradoxically increase anxiety and negative mood
- Higher concentrations (above approximately 10 nM) produce sedation, anxiolysis, and positive mood effects
- Women with PMDD show exaggerated negative responses at low allopregnanolone concentrations due to altered GABA-A receptor subunit composition
- The paradoxical anxiogenic effect is mediated by altered alpha-4/delta subunit expression in GABA-A receptorsConclusion:: Important safety signal for the oral progesterone hypothesis in ME/CFS. Patients who achieve only low-to-moderate allopregnanolone levels (e.g., due to variable first-pass metabolism) may experience worsened anxiety, insomnia, or mood rather than improvement. Women with PMDD or pre-existing mood dysregulation are at elevated risk. Dose titration and monitoring for paradoxical response are essential. Limitations:: Review/analysis paper, not primary RCT; mechanism confirmed in rodent models, human data more limited; thresholds for paradoxical vs beneficial effects are not precisely established in clinical populations. Certainty:: 0.45
9 Gur et al. 2004 — Progesterone Levels Normal in Fibromyalgia and CFS (Null Result)
Full Citation:: Gur A, Cevik R, Nas K, Sarac AJ, Colpan L, Em S. “Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones.” Arthritis Research & Therapy. 2004;6(3):R232–R238. DOI:: 10.1186/ar1163 PMID:: 15142269 Study Design:: Cross-sectional; n=176 women (46 controls, 68 fibromyalgia, 62 CFS); follicular-phase hormone sampling; Beck Depression Inventory for mood. Key Findings::
- NULL RESULT: no significant differences in FSH, LH, estradiol, or progesterone between fibromyalgia/CFS patients and healthy controls
- Cortisol significantly lower in patient groups (consistent with HPA hypocortisolism pattern in ME/CFS)
- Depressive symptoms correlated with lower cortisol but not with HPG hormone levelsConclusion:: Confirms that ME/CFS and fibromyalgia are not characterized by progesterone deficiency. The oral progesterone hypothesis for ME/CFS is therefore a pharmacological intervention (raising progesterone above normal levels to exploit immune and neurosteroid effects) rather than hormone replacement. This is an important interpretive distinction. Limitations:: Follicular phase only (progesterone naturally low; luteal phase not assessed); cross-sectional design; no correlation with symptom severity; early 2003 CFS diagnostic criteria. Certainty:: 0.55
10 Cevik et al. 2004 — HPG Axis Normal Across Menstrual Cycle in CFS (Null Result, Replication)
Full Citation:: Cevik R, Gur A, Acar S, Nas K, Sarac AJ. “Hypothalamic-pituitary-gonadal axis hormones and cortisol in both menstrual phases of women with chronic fatigue syndrome and effect of depressive mood on these hormones.” BMC Musculoskeletal Disorders. 2004;5:47. DOI:: 10.1186/1471-2474-5-47 PMID:: 15588275 Study Design:: Case-control; n=43 CFS, 35 healthy controls; premenopausal women; hormone sampling in both follicular and luteal phases. Key Findings::
- NULL RESULT: no significant differences in FSH, LH, estradiol, or progesterone between CFS patients and controls in either menstrual phase
- Cortisol significantly lower in CFS group in both phases
- Depressive mood did not account for the cortisol difference
- Extends Gur 2004 by measuring both cycle phases, confirming luteal-phase progesterone also normalConclusion:: Together with Gur 2004, provides consistent evidence across two independent cohorts that ME/CFS is not a progesterone-deficiency state. Importantly, normal luteal-phase progesterone (sampled in this study) confirms the baseline is intact — any therapeutic effect of oral progesterone supplementation would be via supraphysiological immune/neurosteroid mechanisms. Limitations:: Small sample; premenopausal only; single-centre; no correlation with ME/CFS severity sub-groups. Certainty:: 0.52